Figure 3From: An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS® hydromorphone in patients with chronic cancer pain BPI pain interference scores at baseline and end point (all patients). BPI scored from 0 = does not interfere to 10 = completely interferes. BPI, brief pain inventory.Back to article page